Inactive Instrument

Aravive, Inc.

Equities

ARAV

US03890D1081

Biotechnology & Medical Research

Versartis, Inc. Names Jay Shepard as Executive Chairman to its Board of Directors

January 08, 2014 at 08:00 am

Versartis, Inc. announced the appointment of Jay Shepard as Executive Chairman to its Board of Directors. Mr. Shepard is an Executive Partner at Sofinnova Ventures. He recently returned to Sofinnova following the successful sale of a Sofinnova portfolio company NextWave Pharmaceutical to Pfizer in late 2012.

Latest news about Aravive, Inc.

Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	01-31	CI
Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	01-26	CI
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	01-19	MT
Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	01-17	MT
Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	01-17	CI
Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	01-17	CI
Aravive, Inc. Announces Board and Committee Resignations	01-17	CI
North American Morning Briefing : Stocks Seen -2-	11-15	DJ
Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
North American Morning Briefing : Nvidia Results -2-	23-08-23	DJ
Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	23-08-22	MT
Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
North American Morning Briefing : Treasury Yields Keep Pushing Higher	23-08-17	DJ
North American Morning Briefing : Stocks Seen -2-	23-08-04	DJ
Sector Update: Health Care Stocks Slipping Late Thursday	23-08-03	MT
Sector Update: Health Care	23-08-03	MT
Top Midday Decliners	23-08-03	MT
EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	23-08-03	MT
HC Wainwright Downgrades Aravive to Neutral From Buy	23-08-03	MT
William Blair Downgrades Aravive to Market Perform From Outperform	23-08-03	MT
BTIG Downgrades Aravive to Neutral From Buy	23-08-03	MT
Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	23-08-02	CI
BTIG Adjusts Price Target on Aravive to $9 From $12, Maintains Buy Rating	23-07-10	MT
Aravive, Inc.(NasdaqGS:ARAV) added to Russell 3000E Growth Index	23-06-23	CI

Chart Aravive, Inc.

Duration

Period

More charts

Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.11%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-16.10%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs